U.S. markets closed

Tetra Bio-Pharma Inc. (TBPMF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.2103-0.0002 (-0.10%)
At close: 3:57PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.2105
Open0.2147
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.2100 - 0.2198
52 Week Range0.0940 - 0.4400
Volume317,341
Avg. Volume822,752
Market Cap85.346M
Beta (5Y Monthly)2.11
PE Ratio (TTM)N/A
EPS (TTM)-0.0900
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Tetra Bio-Pharma Engages Christine Caron as Patient Partner
    PR Newswire

    Tetra Bio-Pharma Engages Christine Caron as Patient Partner

    Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA:JAM1), a leader in cannabinoid-derived drug discovery and development announced today it has engaged Christine Caron as Patient Partner to support significant and active collaboration in research, knowledge translation, and patient engagement within the pain and Sepsis communities.

  • Tetra Bio-Pharma Accelerates REBORN1© Trial
    CNW Group

    Tetra Bio-Pharma Accelerates REBORN1© Trial

    Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development announced today that the Central Ethics Committee has approved the proposed protocol modifications allowing additional immediate release oral opioids to be used as comparators in the REBORN1© study. Expanding to three (3) immediate release oral opioids will allow for the acceleration of patient enrolment in the REBORN1© trial.

  • Horizons ETFs Rebalances Marijuana-Focused Index Etfs
    CNW Group

    Horizons ETFs Rebalances Marijuana-Focused Index Etfs

    Horizons ETFs Management (Canada) Inc. ("Horizons ETFs") has completed the quarterly rebalances of the holdings of the Horizons Marijuana Life Sciences Index ETF ("HMMJ":TSX) and the Horizons US Marijuana Index ETF ("HMUS":NEO).